The rise in the incidence rate of ankylosing spondylitis, the elevating focus on R&D activities, and lack of approval of therapies have resulted in boosting the Ankylosing Spondylitis Drugs market.
Market Size – USD 5.60 Billion in
2018, Market Growth - CAGR of 5.1%, Market Trends – The rising demand for
Ankylosing Spondylitis Drugs in developing regions
The Global Ankylosing Spondylitis Drugs Market is forecast to reach USD 8.82 Billion by 2027, according to a new report by Reports and Data. Ankylosing spondylitis (AS) is a chronic condition that has no permanent cure. It can be defined as an inflammatory disease that results in some of the small bones in the spine (vertebrae) to fuse over time. The fusing of the small bones results in making the spine less flexible and can haunch it in a forward position. In case it affects the rib cage, the patient can have an issue with breathing deeply. The condition effects more men as compared to women. Symptoms and signs associated with condition usually initiates in adulthood.
Get
a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2427
Inflammation associated with the
condition may also occur in other parts of the body like eyes. Early signs
associated with condition may include stiffness and pain in the lower back and hips,
particularly in the morning and after prolonged sitting. Fatigue and neck pain
are also common in AS. Though there is no cure to the condition with effective
medication and treatment, the symptom can be managed and controlled. Various
types of medications may help in stopping or delaying spinal problems and ease
the pain & swelling. In regards to region, Europe, can be seen to occupy a
prominent market share. The market position held by the region is attributed to
high prevalence rate of the condition in this region, along with continuously
expanding healthcare sector.
Further key findings from the report suggest
·
The Ankylosing Spondylitis Drugs
market held a market value of USD 5.60 Billion in the year 2018 that is
forecasted to grow at a rate of 5.1% during the forecast period.
·
In context to Drug Type, the
Nonsteroidal Anti-Inflammatory Drugs segment generated the highest revenue of
USD 2.58 Billion in 2018, with a CAGR of 5.3% during the forecast period. Its
effectiveness in minimizing inflammation, which is a major impact of the
diseases and the main goal of the care services, results in a high demand for
Nonsteroidal Anti-Inflammatory Drugs among care providers that contributes to
the revenue generated by this segment.
·
In context to Route of
Administration, the Parenteral segment is projected to witness a faster growth
rate of 4.3% during the forecast period, which is expected to occupy 35.0% of
the market by 2027. The growth rate witnessed by the segment is attributed to
the presence of strong pipeline products and continuous development in
biologics that are needed to be administered in this way. The fact that
medications, when administered in the form of injectable, works the specific
problem area and given prompt result, have resulted in its growing popularity
care providers.
·
In context to Distribution Channel,
the Online Pharmacy segment is projected to witness the fastest growth rate of
5.8% during the forecast period, which is expected to occupy 26.5% by 2027. The
growth of online medicine shops, rising trend of online purchase of medicine
due to benefits like comfort, convenience, and various offers in these shops
contributes to the growth rate witnessed by this segment.
·
In regards to Application, the Adults
segment generated a higher revenue of USD 4.09 Billion in 2018, with a CAGR of
5.5% during the forecast period. The fact that the signs associated with the
condition usually initiates in adulthood and appears prior to the age of 45
results in higher application of these medications among adults.
·
In regards to the region, Asia
Pacific is projected to witness the fastest growth rate of 5.7% during the
forecast, which is expected to hold 0% of the market by 2027. The growth rate
witnessed by the region is resultant of the expansion of the health care
sector, and increasing focus on R&D activities, which is supporting the
market growth in this region.
·
Key participants include Merck &
Co., Boehringer Ingelheim, UCB, Amgen, Janssen Biotech, Inc., Johnson &
Johnson, Abbvie, Hetero, Zydus Cadila, and Izana Bioscience.
To know more about the report @ https://www.reportsanddata.com/report-detail/ankylosing-spondylitis-drugs-market
For the purpose of this report,
Reports and Data have segmented the global Ankylosing Spondylitis Drugs market,
according to Drug Type, Route of Administration, Distribution Channel,
Application and Region:
Drug Type Outlook (Revenue, USD
Billion; 2016-2027)
·
Nonsteroidal Anti-Inflammatory Drugs
·
Anti-Inflammatory Drugs
·
Immunosuppressive Drugs
·
TNF blockers
·
JAK Inhibitors
·
Steroids
·
Biologics
·
Others
Route of Administration Outlook
(Revenue, USD Billion; 2016-2027)
·
Parenteral
·
Oral
Distribution Channel Outlook
(Revenue, USD Billion; 2016-2027)
·
Hospitals Pharmacy
·
Retail Pharmacy
·
Online Pharmacy
Application Outlook (Revenue,
USD Billion; 2016-2027)
·
Adults
·
Juveniles
Regional Outlook (Revenue, USD
Billion; 2016-2027)
·
North America
o
U.S
·
Europe
o
U.K
o
France
·
Asia Pacific
o
China
o
India
o
Japan
·
MEA
·
Latin America
o
Brazil
Request a customization of the report @
https://www.reportsanddata.com/request-customization-form/2427
Key Questions Answered in the Report:
·
What is
the expected market size of the Ankylosing Spondylitis Drugs market by 2028?
·
What are
the key factors expected to drive and restrain Ankylosing Spondylitis Drugs
market growth over the forecast period?
·
What are
the key products and applications offered by the Ankylosing Spondylitis Drugs
market?
·
Which
region is expected to account for largest revenue share in the market in the
coming years?
·
What are
the current and future market trends of the Ankylosing Spondylitis Drugs
market?
·
Which
segment is expected to show lucrative growth throughout the forecast period?
·
What are
the key outcomes of SWOT analysis and Porter’s Five Forces analysis?
·
Who are
the prominent distributors, vendors, and manufacturers of the market?
·
What are
the key challenges and limitations the new entrants and companies will have to
face in the Ankylosing Spondylitis Drugs market over the forecast period?
Table of Content:
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technology
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2018-2027
Chapter 3. Indicative Metrics
Chapter 4. Ankylosing Spondylitis Drugs Market Segmentation
& Impact Analysis
4.1. Ankylosing Spondylitis Drugs
Market Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market
indicators analysis
4.2.2. Market
drivers analysis
4.2.2.1. The rise in the incidence rate of ankylosing spondylitis
4.2.2.2. Lack of approval of therapies
4.2.2.3. The elevating focus on R&D activities
4.2.3. Market
restraints analysis
4.2.3.1. Limited awareness about the condition that results in
delayed diagnosis
4.3. Technological Insights
4.4. Regulatory Framework
4.5. ETOP Analysis
4.6. Porter’s Five Forces Analysis
4.7. Competitive Metric Space
Analysis
4.8. Price Trend Analysis
Chapter 5. Ankylosing Spondylitis Drugs Market By Drug Type
Insights & Trends
Continued….
Thank
you for reading our report. To know more about the customization or any query
about the report contents, please connect with us and our team will ensure the
report is tailored to meet your requirements.
No comments:
Post a Comment